1-(1'-acetyl-5-(4-fluorophenoxy)spiro[indoline-3,3'-pyrrolidin]-1-yl)-2,2,2-trifluoroethanone

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1'-acetyl-5-(4-fluorophenoxy)spiro[indoline-3,3'-pyrrolidin]-1-yl)-2,2,2-trifluoroethanone
• 英文别名: 1-(1'-Acetyl-5-(4-fluorophenoxy)spiro[indoline-3,3'-pyrrolidin]-1-yl)-2,2,2-trifluoroethanone；1-[1'-acetyl-5-(4-fluorophenoxy)spiro[2H-indole-3,3'-pyrrolidine]-1-yl]-2,2,2-trifluoroethanone
• 化学式: C₂₁H₁₈F₄N₂O₃
• 分子量: 422.379
• InChiKey: HJCHTMIMMZJIRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-(1'-acetyl-5-methoxyspiro[indoline-3,3'-pyrrolidin]-1-yl)-2,2,2-trifluoroethanone 在 copper diacetate 、 三溴化硼 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 1-(1'-acetyl-5-(4-fluorophenoxy)spiro[indoline-3,3'-pyrrolidin]-1-yl)-2,2,2-trifluoroethanone
  参考文献：
  名称：

  EP2781521

  摘要：

  公开号：

文献信息

• NOVEL SPIROINDOLINE COMPOUND, AND MEDICINAL AGENT COMPRISING SAME
  申请人：KOWA COMPANY, LTD.

  公开号：US20140309207A1

  公开（公告）日：2014-10-16

  The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R 1 and R 2 , which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C 1-6 alkyl group, a C 6-10 aryl group, a cyano group, a C 1-6 alkyl group optionally having a substituent, a C 2-6 alkenyl group optionally having a substituent, etc.; R 3 represents a hydrogen atom, a C 1-6 alkyl group optionally having a substituent, etc.; and R 4 represents a hydrogen atom, a halogen atom, a C 1-6 alkyl group optionally having a substituent, etc.]

  本发明提供了一种新型化合物，其通式（1）如下所示，具有在肝脏和胰岛β细胞中激活葡萄糖激酶的作用，并可用作预防和/或治疗由高血糖引起的疾病，如糖尿病的药物。该通式（1）表示的螺环吲哚化合物，或其盐，或化合物或盐的溶剂：[其中环A代表含氮的5-10成员杂环基；R1和R2，相同或不同，分别代表氢原子，卤原子，卤代C1-6烷基，C6-10芳基，氰基，C1-6烷基，可选取代基，C2-6烯基，可选取代基等；R3代表氢原子，C1-6烷基，可选取代基等；R4代表氢原子，卤原子，C1-6烷基，可选取代基等。]
• Spiroindoline compound, and medicinal agent comprising same
  申请人：Kowa Company, Ltd.

  公开号：US08921576B2

  公开（公告）日：2014-12-30

  The present invention provides a novel compound represented by a general formula (1) as shown below, which has a glucokinase-activating action in the liver and pancreatic β-cells and which is useful as an agent for preventing and/or treating diseases caused by hyperglycemia, such as diabetes. A spiroindoline compound represented by the general formula (1), or a salt thereof, or a solvate of the compound or the salt: [wherein ring A represents a nitrogen-containing 5-10 membered heteroaryl group; R1 and R2, which are the same or different, each represent a hydrogen atom, a halogen atom, a halo C1-6 alkyl group, a C6-10 aryl group, a cyano group, a C1-6 alkyl group optionally having a substituent, a C2-6 alkenyl group optionally having a substituent, etc.; R3 represents a hydrogen atom, a C1-6 alkyl group optionally having a substituent, etc.; and R4 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group optionally having a substituent, etc.]

  本发明提供了一种新型化合物，其通式（1）如下所示，具有在肝脏和胰岛β细胞中激活葡萄糖激酶的作用，并且可用作预防和/或治疗由高血糖引起的疾病，如糖尿病的药物。通式（1）表示的螺内酰胺化合物，或其盐，或化合物或盐的溶剂:[其中，环A表示含氮的5-10成员杂环基；R1和R2，它们相同或不同，每个表示氢原子，卤原子，卤代C1-6烷基，C6-10芳基，氰基，可选有取代基的C1-6烷基，可选有取代基的C2-6烯基等；R3表示氢原子，可选有取代基的C1-6烷基等；R4表示氢原子，卤原子，可选有取代基的C1-6烷基等。]
• US8921576B2
  申请人：——

  公开号：US8921576B2

  公开（公告）日：2014-12-30
• EP2781521
  申请人：——

  公开号：——

  公开（公告）日：——